BioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 12.6% in February

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 3,830,000 shares, a decrease of 12.6% from the January 31st total of 4,380,000 shares. Based on an average daily volume of 1,040,000 shares, the days-to-cover ratio is presently 3.7 days.

BioAtla Price Performance

BCAB stock opened at $0.34 on Friday. BioAtla has a 1-year low of $0.24 and a 1-year high of $4.02. The company has a market capitalization of $16.67 million, a price-to-earnings ratio of -0.20 and a beta of 1.19. The business has a 50 day simple moving average of $0.47 and a two-hundred day simple moving average of $1.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd boosted its position in shares of BioAtla by 7.2% during the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after acquiring an additional 10,384 shares during the last quarter. Chicago Partners Investment Group LLC bought a new position in shares of BioAtla during the 3rd quarter valued at approximately $44,000. Massachusetts Financial Services Co. MA boosted its position in shares of BioAtla by 5.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock valued at $1,002,000 after acquiring an additional 28,133 shares during the last quarter. Magnus Financial Group LLC bought a new position in shares of BioAtla during the 4th quarter valued at approximately $28,000. Finally, Two Sigma Investments LP boosted its position in shares of BioAtla by 84.0% during the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after acquiring an additional 61,725 shares during the last quarter. 77.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright downgraded BioAtla from a “buy” rating to a “neutral” rating in a research note on Wednesday, November 13th.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.